Calviri
Phoenix, US · Founded 2015 · Delaware corporation · 1 known investors
Find your way into Calviri
57 people in our graph share verified history with the Calviri team — schools, employers, funds. One of them is your warm intro.
Mike McMahonunlockedknows Stephen Albert Johnston · together at Penn State University (overlapped)
×9knows the team · via Penn State University
knows the team · via Duke University
knows the team · via The University of Texas Southwestern Medical School
Calviri is a biotechnology company developing multi-cancer blood tests and cancer vaccines for dogs and humans, based on antigens said to be shared across tumors. Its first commercial product is StageOne Plus, a canine multi-cancer, multi-stage diagnostic test, and it is also running clinical trials of preventative and therapeutic canine cancer vaccines.
Founders & leadership
Calviri was founded in 2015 by Stephen Albert Johnston.
SA
Stephen Albert Johnstoninco-Founding CEOStephen Albert Johnston developed the SimpleAI system for identifying solutions to biological problems and has authored work on nucleic acid vaccines, gene expression technologies, and diagnostic methods. He currently serves as executive officer at Calviri, focusing on RNA-based vaccine development and diagnostic array technologies.
KS
Kathryn SykesinVice President Research & Product Development
GP
George PosteNamed on SEC filing
NW
Neal WoodburyNamed on SEC filing
AB
Anna BarkerNamed on SEC filing
Board
JJ
Jacque J. SokolovBoard director
MM
Michael McCallisterBoard director
JL
Jeffrey Le BengerBoard director
Investors · 1
Funding
SEC filings, press & company announcements$19.7M disclosed across 8 rounds · 2018–2024
- $2.3MSeedApr 2020 · 3 sourcesSource ↗
▶$785KraisedNov 2024 · 10 investors · BiotechnologyRule 506(b)
▶$785KraisedNov 2024 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kathryn SykesDirector
- Jeffrey Le BengerDirector
- Michael McCallisterDirector
- Stephen Albert JohnstonExecutive Officer, Director
- Jacque J. SokolovDirector
- Offering amount
- $5M
- Amount sold
- $785K
- Minimum investment
- $25K
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$150KraisedSep 2024 · 1 investors · BiotechnologyRule 506(b)
▶$150KraisedSep 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen Albert JohnstonExecutive Officer, Director
- Jacque J. SokolovDirector
- Michael McCallisterDirector
- Jeffrey Le BengerDirector
- Kathryn SykesDirector
- Offering amount
- $2M
- Amount sold
- $150K
- Minimum investment
- $25K
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$650.2KraisedOct 2023 · 3 investors · BiotechnologyRule 506(b)
▶$650.2KraisedOct 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen Albert JohnstonExecutive Officer, Director
- Jacque J. SokolovDirector
- Jeffrey Le BengerDirector
- Michael ChambersDirector
- Kathryn SykesDirector
- Michael McCallisterDirector
- Offering amount
- $30M
- Amount sold
- $650.2K
- Minimum investment
- $10K
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.1MraisedMay 2023 · 32 investors · BiotechnologyRule 506(b)
▶$11.1MraisedMay 2023 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jacque J. SokolovDirector
- Michael McCallisterDirector
- Stephen Albert JohnstonExecutive Officer, Director
- Jeff Le BengerDirector
- Michael ChambersDirector
- Kathryn SykesDirector
- Offering amount
- $11.1M
- Amount sold
- $11.1M
- Minimum investment
- $25K
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedOct 2020 · 5 investors · BiotechnologyRule 506(b)
▶$2.4MraisedOct 2020 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kathryn SykesDirector
- Stephen Albert JohnstonExecutive Officer, Director
- Michael ChambersDirector
- Michael McCallisterDirector
- Jacque J. SokolovDirector
- Offering amount
- $5M
- Amount sold
- $2.4M
- Minimum investment
- $25K
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$430KraisedOct 2020 · 3 investors · BiotechnologyRule 506(b)
▶$430KraisedOct 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kathryn SykesDirector
- Stephen Albert JohnstonExecutive Officer, Director
- Jacque J. SokolovDirector
- Michael ChambersDirector
- Michael McCallisterDirector
- Offering amount
- $5M
- Amount sold
- $430K
- Minimum investment
- $25K
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1.9MraisedMar 2020 · 4 investors · BiotechnologyRule 506(b)
▶$1.9MraisedMar 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- George PosteDirector
- Stephen Albert JohnstonExecutive Officer, Director
- Kathryn SykesDirector
- Neal WoodburyDirector
- Jacque J. SokolovDirector
- Anna BarkerDirector
- Offering amount
- $2.3M
- Amount sold
- $1.9M
- Minimum investment
- $25K
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
KaliVir Immunotherapeutics4 shared keywordsKaliVir develops oncolytic virus immunotherapies for cancer treatment based on its Vaccinia Enhanced Template (VET) backbone, which uses proprietary genetic modifications to a vaccinia virus optimized for intravenous systemic delivery and expression of therapeutic transgenes within tumors. The technology targets tumor replication and metastatic spread while modulating anti-tumoral immunity.
Anivive Lifesciences4 shared keywordsAnivive develops new medicines for companion animals, using software across the drug development process to accelerate the creation of treatments. It serves the animal health community, focusing on veterinary and pet health pharmaceuticals.
Kyverna Therapeutics3 shared keywordsKyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset. The company conducts clinical trials for multiple autoimmune conditions globally.
Triumvira Immunologics3 shared keywordsTriumvira is a clinical-stage immuno-oncology company developing autologous and allogeneic T cell therapeutics for cancer treatment. The company applies T cell biology and targeted immunotherapy approaches to address oncology.
Torigen Pharmaceuticals3 shared keywords
Companies competing with Calviri for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Calviri do?
- Calviri is a biotechnology company developing multi-cancer blood tests and cancer vaccines for dogs and humans, based on antigens said to be shared across tumors. Its first commercial product is StageOne Plus, a canine multi-cancer, multi-stage diagnostic test, and it is also running clinical trials of preventative and therapeutic canine cancer vaccines.
- Who founded Calviri?
- Calviri was founded by Stephen Albert Johnston in 2015.
- Who are Calviri's investors?
- Calviri's investors include Golden Seeds.
- How much funding has Calviri raised?
- Calviri has disclosed $19.7M raised across 8 rounds.
- Where is Calviri headquartered?
- Calviri is headquartered in Phoenix, US.